Rethinking initial injectable therapy for people with type 2 diabetes

Research Review have published a review of  a recent speaker event on; Rethinking initial injectable therapy for people with type 2 diabetes: glucagon-like peptide-1 receptor agonists or basal insulin?

Associate Professor Samantha Hocking from the Royal Prince Alfred Hospital and the University of Sydney reviewed the recently updated ADA/EASD guidelines and provided some guidance.

Associate Mark Kennedy provided an overview of the place of GLP-1 RAs and insulin from the perspective of a general practitioner. Finally, Bernadette Heenan provided an overview of the use of these agents from the perspective of a Credentialed Diabetes Educator working with Indigenous people.

Click below to read the full review.

Speaker Series – Rethinking initial injectable therapy for type 2 diabetes

Please wait...

Subscribe to our Monthly eNews

Receive the latest diabetes news, education, resources and special offers!